AFFiRiS was founded by Dr. Walter Schmidt (CEO) and Dr. Frank Mattner (CSO) in late 2003. Based on its business model and its globally unique expertise, AFFiRiS aims to initiate the clinical testing of a new vaccine against thus-far incurable diseases every 2 to 3 years.
Vienna, 4 June 2014 – AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients. Upon treatment with AD04, effects consistent with disease modification were achieved for at least 18 months in 47 % of treated patients.